References
- Futerman AH , van MeerG. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol.5 (7), 554–565 (2004).
- Grabowski GA . Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet372 (9645), 1263–1271 (2008).
- Zhao H , GrabowskiGA. Gaucher disease: perspectives on a prototype lysosomal disease. Cell. Mol. Life Sci.59 (4), 694–707 (2002).
- Chérin, P, RoseC, de Roux-SerratriceCet al. The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). J. Inherit. Metab. Dis.33 (4), 331–338 (2010).
- Sidransky E . Gaucher disease: complexity in a ‘simple’ disorder. Mol. Genet. Metab.83 (1–2), 6–15 (2004).
- Bennett LL , MohanD. Gaucher disease and its treatment options. Ann. Pharmacother.47 (9), 1182–1193 (2013).
- Leidenheimer NJ , RyderKG. Pharmacological chaperoning: a primer on mechanism and pharmacology. Pharmacol. Res.83C, 10–19 (2014).
- Boyd RE , LeeG, RybczynskiPet al. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J. Med. Chem.56 (7), 2705–2725 (2013).
- Parenti G . Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol. Med.1 (5), 268–279 (2009).
- Suzuki Y , OgawaS, SakakibaraY. Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect. Med. Chem.3, 7–19 (2009).
- Trapero A , LlebariaA. Glucocerebrosidase inhibitors for the treatment of Gaucher disease. Future Med. Chem.5 (5), 573–590 (2013).
- Benito JM , García FernándezJM, Ortiz MelletC. Pharmacological chaperone therapy for Gaucher disease: a patent review. Expert Opin. Ther. Pat.21 (6), 885–903 (2011).
- Patnaik S , ZhengW, ChoiJHet al. Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J. Med. Chem.55 (12), 5734–5748 (2012).
- Conn PJ , ChristopoulosA, LindsleyCW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov.8 (1), 41–54 (2009).
- Amicus Therapeutics announces preliminary results of Phase II study with plicera for Gaucher disease. http://ir.amicustherapeutics.com/ReleaseDetail.cfm?ReleaseID=413437
- Maegawa GH , TropakMB, ButtnerJDet al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem.284 (35), 23502–23516 (2009).
- Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease. http://clinicaltrials.gov/ct2/show/NCT01463215
- Vaquer G , RivièreF, MavrisMet al. Animal models for metabolic, neuromuscular and ophthalmological rare diseases. Nat. Rev. Drug Discov.12 (4), 287–305 (2013).
- Farfel-Becker T , VitnerEB, FutermanAH. Animal models for Gaucher disease research. Dis. Model. Mech.4 (6), 746–752 (2011).
- Sanders A , HemmelgarnH, MelroseHL, HeinL, FullerM, ClarkeLA. Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease. Blood Cells Mol. Dis.51 (2), 109–115 (2013).